Chinese Healthcare Investors

Chinese firm China Medical System Holdings is investing $12 million in UK healthcare firm Blueberry Therapeutics.

Established in 2011, Blueberry Therapeutics is a UK-based drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections. China Medical System Holdings is a specialty pharmaceutical company based in China, focusing on marketing, promotion and sales of prescription drugs and other medicinal products. (More details here.)

To see a listing and email addresses of investors from China similar to China Medical System Holdings, check the Chinese Investors Directory.

A consortium of Chinese investment firms have acquired stake in SciClone, a California Pharmaceutical firm, for $605 million.

Headquartered in Foster City California and listed on NASDAQ, SciClone is a revenue-generating pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. (The buyer consortium consists of entities affiliated with GL Capital Management founded by Jeffrey Li, Bank of China Group Investment, CDH Investments, Ascendent Capital Partners, and Boying Investments of Weihang Zhu).

CDH Investments is listed in the Chinese Private Equity and Venture Capital Directory with the code OR41.

More details follows:

Chinese firm Xiwang has acquired Canada's nutrition supplement maker Iovate Health for $730 million.

Founded in 1995 and based in Oakville, Canada with 330 employees, Iovate products are sold in more than 130 countries worldwide. Founded in 2007 based in Shandong Province, China with consolidated revenue in excess of $5 billion, Xiwang Food is a leading Chinese player in healthy consumable oils such as corn oil and flaxseed oil.

To see a list of investors from China similar to Xiwang, check the Chinese Investors Directory.

More details follows

Chinese private equity firm Primavera Capital and Shanghai Pharmaceuticals has acquired Australian vitamins maker Vitaco Holdings for $239 million.

Established in 2007 and employing 400, Vitaco is an Australian supplement manufacturer, distributing in 30 countries and producing 1 billion products every year. Primavera Capital Group is a private equity firm investing in companies in China and around the world. It was founded in 2010 and is based in Beijing with offices in Shanghai and Hong Kong. (According to Reuters, this buyout comes less than a year after Hong Kong-listed Biostime International Holdings bought Australian vitamin maker Swisse Wellness for around $1 billion in 2015).

Primavera Capital is listed in the Chinese Investors Directory with the code SIJ26.

More details follows from Reuters

Continue reading "Chinese investors acquired Australian vitamin maker Vitaco for $239 million" »

Hong Kong-based venture capital group ORI Healthcare Fund has announced investment of $18 million into Pillar Biosciences, a Boston-based cancer research firm.

Pillar Biosciences is developing technologies and products for cancer diagnostics driven by next-generation sequencing (NGS). ORI Fund is a $200 million venture capital fund focused on investing in the healthcare industry globally. The fund is founded by Ms. Simone Hong Fang Song, former investment banker and head of China Healthcare at Goldman Sachs.

To see a list of investors from China similar to ORI Healthcare Fund, check the Chinese Investors Directory.

More details follows:

Continue reading "Chinese investors of ORI Capital invested $18 million in Boston firm Pillar Biosciences " »

Citic Private Equity, a Chinese private equity firm, has acquired stake at Biosensors International Group, a Singapore-based medical device maker, for $817 million.

Citic Private Equity Funds Management already controls about 19.6 percent of Biosensors. Biosensors International Group is a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care. The company was listed in the Mainboard of the Singapore Exchange (SGX) in May 2005. (CITIC Capital Partners, the private equity arm of CITIC Capital, invests globally, operates in China, Japan and the US and manages $2.6 billion of committed capital.)

Citic Private Equity is listed in the Chinese Private Equity and Venture Capital Directory with the code OR48

More details follows from Bloomberg

Continue reading "Chinese investors of Citic acquired stake at Singapore medical firm for $817 million" »

Shenzhen Hepalink, a Chinese provider of material to global pharma firms, has acquired Cytovance Biologics, a US Oklahoma City bio-pharma manufacturing firm, for $205 million

Established in 2003 and based in US Oklahoma City, Cytovance Biologics is a biopharmaceutical contract manufacturing company, specializing in the production of therapeutic proteins and antibodies. Established in 1998 and listed on the Shenzhen Stock Exchange, Hepalink is a provider of Heparin Sodium API to pharmaceutical companies, such as Sanofi-Aventis, Fresenius -Kabi and Novartis.

To see a list of investors from China similar to Shenzhen Hepalink, check the Chinese Investors Directory.

More details follows:

Continue reading "Chinese Hepalink acquired US Cytovance Biologics for $205 million" »

Guangxi Wuzhou Zhongheng Group, a Chinese investment holdings company, through its subsidiary has invested $3 million in Israeli biotechnology firm Integra Holdings.

Integra Holdings, founded in 2012, has a portfolio of companies operating in a variety of therapeutic areas such as oncology, Alzheimer's disease and infectious diseases. Integra Holdings has raised a total of $12 million to date.

Guangxi Wuzhou Zongheng Group is listed in the Chinese Investors Directory with the code XJO31

More details follows

Continue reading "Chinese investors acquired stake at Israeli biotech firm for $3 million" »